# Baseline characteristics before and after PS stratification

## HCQ vs. SSZ: IPCI

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | Before stratification |  |  | After stratification |  |  |
|  | HCQ | SSZ |  | HCQ | SSZ |  |
| Characteristic | % | % | Std. diff | % | % | Std. diff |
| Age group |  |  |  |  |  |  |
| 15-19 | 0.4 | <0.9 | 0.00 | 0.4 | <0.9 | 0.02 |
| 20-24 | 0.6 | 1.3 | -0.07 | 0.6 | 1.0 | -0.04 |
| 25-29 | 1.4 | 3.0 | -0.11 | 1.5 | 2.7 | -0.08 |
| 30-34 | 1.6 | 4.4 | -0.16 | 1.8 | 3.7 | -0.12 |
| 35-39 | 3.2 | 4.0 | -0.04 | 3.4 | 4.0 | -0.03 |
| 40-44 | 6.0 | 4.4 | 0.08 | 6.4 | 3.4 | 0.14 |
| 45-49 | 8.5 | 10.4 | -0.06 | 9.0 | 10.1 | -0.04 |
| 50-54 | 10.5 | 9.7 | 0.03 | 11.0 | 9.1 | 0.06 |
| 55-59 | 11.2 | 14.6 | -0.10 | 11.5 | 14.4 | -0.09 |
| 60-64 | 12.2 | 12.3 | 0.00 | 11.7 | 12.7 | -0.03 |
| 65-69 | 11.8 | 12.9 | -0.03 | 11.9 | 12.4 | -0.02 |
| 70-74 | 12.3 | 9.8 | 0.08 | 12.0 | 10.6 | 0.04 |
| 75-79 | 9.0 | 8.5 | 0.02 | 8.8 | 9.8 | -0.04 |
| 80-84 | 7.4 | 3.2 | 0.19 | 6.7 | 4.3 | 0.11 |
| 85-89 | 2.8 | 0.9 | 0.14 | 2.7 | 1.4 | 0.09 |
| 90-94 | 0.8 | <0.9 | 0.09 | 0.8 | <0.9 | 0.08 |
| Gender: female | 68.4 | 68.0 | 0.01 | 68.6 | 67.2 | 0.03 |
| Medical history: General |  |  |  |  |  |  |
| Acute respiratory disease | 14.1 | 16.1 | -0.06 | 14.3 | 16.2 | -0.05 |
| Attention deficit hyperactivity disorder | <0.3 | <0.9 | -0.03 | <0.3 | <0.9 | -0.01 |
| Depressive disorder | 4.7 | 4.2 | 0.02 | 4.8 | 4.5 | 0.02 |
| Diabetes mellitus | 8.6 | 8.9 | -0.01 | 8.2 | 9.9 | -0.06 |
| Gastroesophageal reflux disease | 0.7 | <0.9 | 0.02 | 0.7 | <0.9 | 0.04 |
| Gastrointestinal hemorrhage | 1.1 | 1.9 | -0.07 | 1.0 | 1.8 | -0.07 |
| Hyperlipidemia | 3.4 | 4.0 | -0.03 | 3.4 | 4.3 | -0.05 |
| Hypertensive disorder | 16.3 | 17.6 | -0.04 | 15.6 | 17.6 | -0.06 |
| Obesity | 1.1 | 1.1 | 0.00 | 1.2 | 1.1 | 0.01 |
| Osteoarthritis | 9.7 | 6.4 | 0.12 | 9.4 | 6.7 | 0.10 |
| Pneumonia | 4.1 | 4.5 | -0.02 | 3.9 | 4.4 | -0.02 |
| Psoriasis | 1.1 | 2.8 | -0.12 | 1.2 | 2.5 | -0.09 |
| Renal impairment | 2.1 | 1.5 | 0.04 | 2.0 | 1.4 | 0.05 |
| Ulcerative colitis | <0.3 | 0.9 | -0.10 | <0.3 | 1.1 | -0.12 |
| Urinary tract infectious disease | 9.1 | 7.4 | 0.06 | 9.0 | 7.0 | 0.08 |
| Visual system disorder | 13.3 | 13.4 | 0.00 | 13.4 | 12.1 | 0.04 |
| Medical history: Cardiovascular disease |  |  |  |  |  |  |
| Atrial fibrillation | 2.9 | 2.3 | 0.04 | 2.7 | 2.3 | 0.02 |
| Cerebrovascular disease | 2.6 | 3.0 | -0.03 | 2.4 | 3.4 | -0.06 |
| Coronary arteriosclerosis | 0.5 | <0.9 | 0.05 | 0.5 | <0.9 | 0.07 |
| Heart disease | 10.2 | 9.1 | 0.04 | 9.7 | 10.0 | -0.01 |
| Heart failure | 1.6 | 1.1 | 0.04 | 1.5 | 1.4 | 0.01 |
| Ischemic heart disease | 4.5 | 4.4 | 0.00 | 4.3 | 5.0 | -0.03 |
| Peripheral vascular disease | 3.6 | 4.4 | -0.04 | 3.7 | 4.6 | -0.05 |
| Pulmonary embolism | 0.4 | <0.9 | -0.02 | 0.4 | <0.9 | -0.01 |
| Venous thrombosis | 1.4 | 0.9 | 0.04 | 1.4 | <0.9 | 0.07 |
| Medical history: Neoplasms |  |  |  |  |  |  |
| Malignant lymphoma | <0.3 | <0.9 | -0.02 | <0.3 | <0.9 | 0.01 |
| Malignant neoplasm of anorectum | 0.5 | <0.9 | -0.04 | 0.4 | <0.9 | -0.04 |
| Malignant neoplastic disease | 4.5 | 4.4 | 0.01 | 4.5 | 4.3 | 0.01 |
| Malignant tumor of breast | 1.1 | <0.9 | 0.06 | 1.2 | <0.9 | 0.10 |
| Malignant tumor of lung | 0.5 | 0.9 | -0.06 | 0.5 | 1.3 | -0.09 |
| Medication use |  |  |  |  |  |  |
| Agents acting on the renin-angiotensin system | 29.6 | 23.5 | 0.14 | 28.0 | 26.6 | 0.03 |
| Antibacterials for systemic use | 30.4 | 29.5 | 0.02 | 30.4 | 29.1 | 0.03 |
| Antidepressants | 12.8 | 13.6 | -0.02 | 12.8 | 13.8 | -0.03 |
| Antiepileptics | 5.0 | 4.9 | 0.00 | 5.0 | 5.6 | -0.03 |
| Antiinflammatory and antirheumatic products | 42.7 | 45.1 | -0.05 | 42.5 | 42.9 | -0.01 |
| Antineoplastic agents | 42.5 | 41.1 | 0.03 | 41.2 | 45.5 | -0.09 |
| Antipsoriatics | 0.7 | <0.9 | 0.00 | 0.8 | 0.9 | 0.00 |
| Antithrombotic agents | 22.2 | 18.4 | 0.10 | 20.5 | 22.6 | -0.05 |
| Beta blocking agents | 24.0 | 21.4 | 0.06 | 22.7 | 24.2 | -0.04 |
| Calcium channel blockers | 16.0 | 12.5 | 0.10 | 15.2 | 14.5 | 0.02 |
| Diuretics | 25.3 | 23.1 | 0.05 | 24.0 | 24.5 | -0.01 |
| Drugs for acid related disorders | 66.9 | 67.8 | -0.02 | 66.0 | 67.6 | -0.03 |
| Drugs for obstructive airway diseases | 25.4 | 26.7 | -0.03 | 25.6 | 26.8 | -0.03 |
| Drugs used in diabetes | 11.5 | 11.4 | 0.00 | 11.0 | 13.9 | -0.09 |
| Immunosuppressants | 44.8 | 46.8 | -0.04 | 44.0 | 49.1 | -0.10 |
| Lipid modifying agents | 29.3 | 25.0 | 0.10 | 27.6 | 29.5 | -0.04 |
| Opioids | 20.8 | 21.2 | -0.01 | 20.6 | 22.7 | -0.05 |
| Psycholeptics | 19.5 | 19.3 | 0.01 | 19.4 | 19.9 | -0.01 |
| Psychostimulants, agents used for adhd and nootropics | 0.9 | 1.1 | -0.03 | 0.9 | 1.7 | -0.07 |

## AZM vs. AMX: IPCI

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | Before stratification |  |  | After stratification |  |  |
|  | AZM | AMX |  | AZM | AMX |  |
| Characteristic | % | % | Std. diff | % | % | Std. diff |
| Age group |  |  |  |  |  |  |
| 20-24 | <4.1 | <1.0 | 0.05 | <4.1 | <1.0 | 0.05 |
| 35-39 | <4.1 | <1.0 | 0.19 | <4.1 | <1.0 | 0.19 |
| 40-44 | 6.6 | 4.6 | 0.09 | 6.6 | 4.6 | 0.09 |
| 45-49 | 9.1 | 6.6 | 0.09 | 9.1 | 6.6 | 0.09 |
| 50-54 | 7.4 | 6.8 | 0.02 | 7.4 | 6.8 | 0.02 |
| 55-59 | 8.3 | 11.0 | -0.09 | 8.3 | 11.0 | -0.09 |
| 60-64 | 13.2 | 14.9 | -0.05 | 13.2 | 14.9 | -0.05 |
| 65-69 | 16.5 | 10.6 | 0.18 | 16.5 | 10.6 | 0.18 |
| 70-74 | 12.4 | 13.5 | -0.03 | 12.4 | 13.5 | -0.03 |
| 75-79 | 9.9 | 11.8 | -0.06 | 9.9 | 11.8 | -0.06 |
| 80-84 | 8.3 | 8.9 | -0.02 | 8.3 | 8.9 | -0.02 |
| 85-89 | <4.1 | 6.8 | -0.16 | <4.1 | 6.8 | -0.16 |
| Gender: female | 65.3 | 72.0 | -0.15 | 65.3 | 72.0 | -0.15 |
| Medical history: General |  |  |  |  |  |  |
| Acute respiratory disease | 37.2 | 31.9 | 0.11 | 37.2 | 31.9 | 0.11 |
| Depressive disorder | <4.1 | 3.7 | -0.02 | <4.1 | 3.7 | -0.02 |
| Diabetes mellitus | 6.6 | 8.3 | -0.06 | 6.6 | 8.3 | -0.06 |
| Gastrointestinal hemorrhage | <4.1 | 1.7 | 0.06 | <4.1 | 1.7 | 0.06 |
| Hyperlipidemia | <4.1 | 2.7 | -0.14 | <4.1 | 2.7 | -0.14 |
| Hypertensive disorder | 19.0 | 17.6 | 0.04 | 19.0 | 17.6 | 0.04 |
| Obesity | <4.1 | 1.4 | 0.12 | <4.1 | 1.4 | 0.12 |
| Osteoarthritis | 4.1 | 7.0 | -0.13 | 4.1 | 7.0 | -0.13 |
| Pneumonia | 14.9 | 14.9 | 0.00 | 14.9 | 14.9 | 0.00 |
| Renal impairment | <4.1 | 3.5 | -0.06 | <4.1 | 3.5 | -0.06 |
| Ulcerative colitis | <4.1 | <1.0 | 0.15 | <4.1 | <1.0 | 0.15 |
| Urinary tract infectious disease | 9.9 | 18.8 | -0.26 | 9.9 | 18.8 | -0.26 |
| Visual system disorder | 21.5 | 15.9 | 0.14 | 21.5 | 15.9 | 0.14 |
| Medical history: Cardiovascular disease |  |  |  |  |  |  |
| Atrial fibrillation | <4.1 | 4.1 | -0.04 | <4.1 | 4.1 | -0.04 |
| Cerebrovascular disease | <4.1 | 2.7 | -0.01 | <4.1 | 2.7 | -0.01 |
| Heart disease | 12.4 | 14.5 | -0.06 | 12.4 | 14.5 | -0.06 |
| Heart failure | 4.1 | 3.5 | 0.03 | 4.1 | 3.5 | 0.03 |
| Ischemic heart disease | 4.1 | 6.0 | -0.08 | 4.1 | 6.0 | -0.08 |
| Peripheral vascular disease | <4.1 | 5.0 | -0.25 | <4.1 | 5.0 | -0.25 |
| Venous thrombosis | <4.1 | 1.0 | -0.02 | <4.1 | <1.0 | -0.02 |
| Medical history: Neoplasms |  |  |  |  |  |  |
| Malignant neoplastic disease | 7.4 | 7.7 | -0.01 | 7.4 | 7.7 | -0.01 |
| Medication use |  |  |  |  |  |  |
| Agents acting on the renin-angiotensin system | 34.7 | 35.4 | -0.02 | 34.7 | 35.4 | -0.01 |
| Antibacterials for systemic use | 48.8 | 47.0 | 0.04 | 48.8 | 47.0 | 0.04 |
| Antidepressants | 18.2 | 19.9 | -0.04 | 18.2 | 19.9 | -0.04 |
| Antiepileptics | 9.1 | 8.9 | 0.01 | 9.1 | 8.9 | 0.01 |
| Antiinflammatory and antirheumatic products | 36.4 | 41.8 | -0.11 | 36.4 | 41.8 | -0.11 |
| Antineoplastic agents | 46.3 | 48.4 | -0.04 | 46.3 | 48.4 | -0.04 |
| Antipsoriatics | <4.1 | 1.9 | -0.09 | <4.1 | 1.9 | -0.09 |
| Antithrombotic agents | 30.6 | 32.5 | -0.04 | 30.6 | 32.5 | -0.04 |
| Beta blocking agents | 27.3 | 31.9 | -0.10 | 27.3 | 31.9 | -0.10 |
| Calcium channel blockers | 19.8 | 20.3 | -0.01 | 19.8 | 20.3 | -0.01 |
| Diuretics | 32.2 | 32.9 | -0.02 | 32.2 | 32.9 | -0.02 |
| Drugs for acid related disorders | 77.7 | 80.3 | -0.06 | 77.7 | 80.3 | -0.06 |
| Drugs for obstructive airway diseases | 54.5 | 42.0 | 0.25 | 54.5 | 42.0 | 0.25 |
| Drugs used in diabetes | 13.2 | 12.0 | 0.04 | 13.2 | 12.0 | 0.04 |
| Immunosuppressants | 53.7 | 52.4 | 0.03 | 53.7 | 52.4 | 0.03 |
| Lipid modifying agents | 34.7 | 38.1 | -0.07 | 34.7 | 38.1 | -0.07 |
| Opioids | 24.8 | 28.8 | -0.09 | 24.8 | 28.8 | -0.09 |
| Psycholeptics | 33.9 | 27.3 | 0.14 | 33.9 | 27.3 | 0.14 |
| Psychostimulants, agents used for adhd and nootropics | <4.1 | <1.0 | 0.15 | <4.1 | <1.0 | 0.15 |